Laurus Labs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Results
Laurus Labs share price Rs 1,946.30 on 11 September 2026, down 0.44%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 362.00 crore. Q2 FY26 base a profit of Rs 194.00 crore.
Quick Answer
The Laurus Labs Q2 results date for FY27 is not confirmed, and Laurus Labs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,653.00 crore in revenue and a profit of Rs 194.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Laurus Labs Q2 results FY27 announcement is the next scheduled earnings event for Laurus Labs Ltd., a Hyderabad based pharmaceutical company making active pharmaceutical ingredients and finished dosage formulations, with a large antiretroviral franchise and a growing contract development and manufacturing business for global innovators. The stock traded at Rs 1,946.30 on the NSE on 11 September 2026, down 0.44% from the previous close of Rs 1,955.00, about 0.4% below its 52-week high of Rs 1,955.00 and 241.4% above its 52-week low of Rs 570.10.
What makes the Laurus Labs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,653.00 crore of revenue and a profit of Rs 194.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,026.00 crore and a profit of Rs 362.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Laurus Labs Q2 Results FY27 Date?
The Laurus Labs Q2 results date for FY27 is not confirmed. As of 11 September 2026, Laurus Labs Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Laurus Labs Q2 results date becomes public through that filing rather than through any advance announcement.
The Laurus Labs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Laurus Labs.
Laurus Labs Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Laurus Labs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Laurus Labs. The Laurus Labs Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is revenue, which was Rs 1,653 crore in September 2025 against Rs 2,026 crore in Q1 FY27, a rise of about 23%. Revenue has grown in every one of the five quarters shown.
The second is the operating margin, which was 24% in September 2025 and 32% in Q1 FY27. Margin has expanded in every step of the series, from 24% to 27% to 28% to 32%, and that is the clearest trend in the statement.
The third is whether that margin expansion continues. Net profit more than doubled from Rs 162 crore to Rs 362 crore across five quarters while revenue rose only 29%, so almost all of the profit growth came from margin rather than from volume.
Check Laurus Labs Ltd. Live Fundamentals on the Univest Screener
Laurus Labs Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Laurus Labs Ltd. reported revenue of Rs 2,026.00 crore in Q1 FY27, up 29.04% from Rs 1,570.00 crore in Q1 FY26, and a profit of Rs 362.00 crore at the net level, up 123.46% from Rs 162.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 11.81% over the March 2026 quarter figure of Rs 1,812.00 crore, and net profit was up 28.37% from Rs 282.00 crore in Q4 FY26. Operating margin stood at 32% in Q1 FY27 against 24% in the September 2025 quarter, which is the comparison the Laurus Labs Q2 results print will be read against.
Q2 FY26 Base: The Comparison Laurus Labs Q2 Results FY27 Must Beat
Laurus Labs Ltd. reported revenue of Rs 1,653.00 crore and a profit of Rs 194.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Laurus Labs Q2 results preview.
Net profit in that base quarter was below the Rs 362.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,653.00 crore sits below the Rs 2,026.00 crore of the June 2026 quarter, which frames how much sequential movement the Laurus Labs Q2 results print needs to show growth.
Laurus Labs Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 1,653.00 | 194.00 |
| Q3 FY26 (Dec 2025) | 1,778.00 | 252.00 |
| Q4 FY26 (Mar 2026) | 1,812.00 | 282.00 |
| Q1 FY27 (Jun 2026) | 2,026.00 | 362.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Laurus Labs Q2 results preview uses.
Revenue across those four quarters ranged from Rs 1,653.00 crore to Rs 2,026.00 crore, and net profit from Rs 194.00 crore to Rs 362.00 crore. That spread is the honest context for the Laurus Labs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Laurus Labs Q2 Results FY27
The Laurus Labs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Laurus Labs has already reported.
The CDMO Mix Drives the Margin
Contract development and manufacturing work for innovator companies carries materially better margins than generic antiretroviral ingredients, so a shift in mix towards that business lifts profitability without needing more revenue. Project timing decides which quarter it lands in.
Antiretroviral Tenders Are Lumpy
The generic antiretroviral business supplies global health programmes that buy through periodic tenders, so shipment schedules rather than underlying demand decide the quarter. That is a different cycle from the innovator work and the two rarely peak together.
The Multiple Is Demanding
A price to earnings ratio of 96.36 on trailing earnings per share of Rs 20.20 sits against return on equity of 18.3%, and the price to book ratio is 19.82. The stock trades at Rs 1,946.30, close to a 52-week high of Rs 1,955.00, with a 14-day RSI of 69.83.
Laurus Labs Q2 Results FY27: Share Price and Valuation Going Into the Print
Laurus Labs share price today is Rs 1,946.30 on the NSE, down Rs 8.70 or 0.44% from the previous close of Rs 1,955.00 on 11 September 2026, ahead of the Laurus Labs Q2 results announcement.
| Metric | Value (11 September 2026) |
|---|---|
| NSE Symbol | LAURUSLABS |
| Current Market Price | Rs 1,946.30 |
| 52-Week High | Rs 1,955.00 |
| 52-Week Low | Rs 570.10 |
| Market Capitalisation | Rs 1,05,365 crore |
| PE Ratio | 96.36 |
| PB Ratio | 19.82 |
| EPS (TTM) | Rs 20.20 |
| Book Value per Share | Rs 98.20 |
| Debt to Equity | 0.48 |
| Return on Equity | 18.3% |
| 50-Day Moving Average | Rs 1,757.72 |
| 200-Day Moving Average | Rs 1,289.73 |
| RSI (14) | 69.83 |
The stock trades above both its 50-day average of Rs 1,757.72 and its 200-day average of Rs 1,289.73, with a 14-day RSI of 69.83. None of this is a view on where the shares go once the Laurus Labs Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Laurus Labs Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Laurus Labs Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Laurus Labs Q2 results print in proportion.
- Revenue against the Rs 1,653.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 194.00 crore in that same quarter
- Operating margin against 32% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Laurus Labs Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Laurus Labs Q2 Results FY27
The Laurus Labs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Laurus Labs Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Laurus Labs Q2 results FY27 print faces a base of Rs 1,653.00 crore in revenue and a profit of Rs 194.00 crore, with the most recent quarter having delivered Rs 2,026.00 crore and a profit of Rs 362.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Laurus Labs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Laurus Labs Q2 Results FY27
What is the Laurus Labs Q2 results date for FY27?
Ans. The Laurus Labs Q2 results date for FY27 is not confirmed. Laurus Labs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Laurus Labs Q2 results 2026 cover?
Ans. The Laurus Labs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Laurus Labs Ltd. reports revenue, operating profit and net profit for that period, and the Laurus Labs Q2 results filing also carries the notes to the accounts.
What were the Laurus Labs Q1 FY27 results?
Ans. Laurus Labs Ltd. reported revenue of Rs 2,026.00 crore in Q1 FY27 and a profit of Rs 362.00 crore at the net level. Revenue was up 29.04% versus Q1 FY26 and net profit was up 123.46% from Rs 162.00 crore in Q1 FY26.
What were Laurus Labs Q2 FY26 results in the September 2025 quarter?
Ans. Laurus Labs Ltd. reported revenue of Rs 1,653.00 crore and a profit of Rs 194.00 crore in Q2 FY26. Operating margin was 24%. Those figures form the base for the Laurus Labs Q2 results FY27 comparison.
What are the main Laurus Labs Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Laurus Labs Q2 results expectations centre on revenue against the Rs 1,653.00 crore base, net profit against a profit of Rs 194.00 crore, operating margin against 32% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Laurus Labs share price today ahead of the Q2 earnings?
Ans. Laurus Labs share price is Rs 1,946.30 on the NSE as of 11 September 2026, down 0.44% from Rs 1,955.00. The stock is about 0.4% below its 52-week high of Rs 1,955.00 and 241.4% above its 52-week low of Rs 570.10, at a market capitalisation of Rs 1,05,365 crore.
Is Laurus Labs a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Laurus Labs Ltd. The stock trades at a price-to-book ratio of 19.82 with a return on equity of 18.3%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
